ACM
TGTX icon

Accent Capital Management’s TG Therapeutics TGTX Stock Holding History

Accent Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8K Buy
214
+50
+30% +$2.05K 0.01% 204
2026
Q1 		$5.45K Hold
164
– – ﹤0.01% 272
2025
Q4 		$4.89K Hold
164
– – ﹤0.01% 303
2025
Q3 		$5.92K Hold
164
– – ﹤0.01% 293
2025
Q2 		$5.9K Buy
+164
New +$6.11K ﹤0.01% 314

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Accent Capital Management's TGTX Position: Q2 2026 in Review

Accent Capital Management increased its TG Therapeutics (TGTX) stake by 30% in Q2 2026, buying an estimated $2.05K and bringing the position to 214 shares worth $11.8K. The position accounts for 0.01% of the portfolio, ranked #204.

Accent Capital Management first reported a position in TGTX in Q2 2025 and has held it in 5 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Accent Capital Management held 214 shares of TG Therapeutics worth $11.8K as of Q2 2026.
  • Accent Capital Management bought 50 TG Therapeutics shares in Q2 2026, an estimated $2.05K.
  • TG Therapeutics made up 0.01% of Accent Capital Management's portfolio in Q2 2026, its #204 holding.
  • Accent Capital Management first reported a position in TG Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.